Tesamorelin is a modified version of GHRH, the growth hormone releasing hormone your hypothalamus produces naturally. It binds GHRH receptors in the pituitary and triggers your own pulsatile GH release, which is a different and generally safer proposition than injecting synthetic HGH directly. It received FDA approval in 2010 under the brand name Egrifta, specifically for reducing visceral fat in HIV patients with lipodystrophy.
The headline number: Phase 3 trials showed 15 to 26 percent reductions in visceral adipose tissue over 26 weeks. That is human trial data, not rat studies, which makes tesamorelin unusual in this category. I am not going to rehash the mechanism, dosing tables, and side-effect profile here. The tesamorelin peptide profile carries all of that. This page is about getting it, or deciding not to bother, inside the Philippines.
